CR7804A - Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico - Google Patents
Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasicoInfo
- Publication number
- CR7804A CR7804A CR7804A CR7804A CR7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- syndrome
- myelodisplasic
- acute leukemia
- combined therapy
- Prior art date
Links
- 206010000830 Acute leukaemia Diseases 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
- E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
- E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
- E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/035532 WO2004043461A1 (en) | 2002-11-06 | 2002-11-06 | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7804A true CR7804A (es) | 2008-10-29 |
Family
ID=32311637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7804A CR7804A (es) | 2002-11-06 | 2005-04-25 | Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1575582A4 (no) |
| JP (1) | JP2006508119A (no) |
| CN (1) | CN1720044A (no) |
| AU (2) | AU2002348178A1 (no) |
| BR (1) | BR0215935A (no) |
| CA (1) | CA2504611A1 (no) |
| CR (1) | CR7804A (no) |
| MX (1) | MXPA05004711A (no) |
| NO (1) | NO20052009L (no) |
| WO (1) | WO2004043461A1 (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006050075A2 (en) * | 2004-10-29 | 2006-05-11 | Regents Of The University Of California | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |
| EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| KR20080030659A (ko) * | 2005-07-06 | 2008-04-04 | 카니사 파마슈티컬즈, 인크. | 칼리키아미신-항체 컨쥬게이트를 조스퀴다르와 조합하여사용하는 암 환자의 치료 |
| ES2371085T3 (es) * | 2006-05-27 | 2011-12-27 | Faulstich, Heinz, Dr. | Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación. |
| CN1994293A (zh) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | 冬凌草甲素在制药中的应用 |
| AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| PL3300601T3 (pl) * | 2007-02-16 | 2022-05-02 | Rotalec Ip Holdings Llc | Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych |
| EP2249831A2 (en) * | 2007-12-10 | 2010-11-17 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US20110159507A1 (en) | 2008-08-29 | 2011-06-30 | School Juridical Person The Kitasato Institute | Method for detecting the drug effects of dna methylation-inhibitors |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017210621A1 (en) * | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| AR112202A1 (es) * | 2017-06-22 | 2019-10-02 | Servier Lab | Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| IL285155B2 (en) * | 2019-01-28 | 2026-01-01 | Univ Texas | Therapy using metal chelators to treat cancer |
| CN110123825B (zh) * | 2019-05-28 | 2021-11-30 | 宁波市鄞州人民医院 | 一种包含去甲氧柔红霉素的药物组合物 |
| WO2022093983A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2025214401A1 (zh) * | 2024-04-12 | 2025-10-16 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物、组合物及其用途和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| CA2418014C (en) * | 2000-08-08 | 2014-01-21 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
-
2002
- 2002-11-06 WO PCT/US2002/035532 patent/WO2004043461A1/en not_active Ceased
- 2002-11-06 AU AU2002348178A patent/AU2002348178A1/en not_active Abandoned
- 2002-11-06 JP JP2004551359A patent/JP2006508119A/ja active Pending
- 2002-11-06 BR BR0215935-0A patent/BR0215935A/pt not_active IP Right Cessation
- 2002-11-06 EP EP02784400A patent/EP1575582A4/en not_active Withdrawn
- 2002-11-06 CN CNA028301404A patent/CN1720044A/zh active Pending
- 2002-11-06 MX MXPA05004711A patent/MXPA05004711A/es active IP Right Grant
- 2002-11-06 CA CA002504611A patent/CA2504611A1/en not_active Abandoned
-
2005
- 2005-04-25 NO NO20052009A patent/NO20052009L/no not_active Application Discontinuation
- 2005-04-25 CR CR7804A patent/CR7804A/es not_active Application Discontinuation
-
2010
- 2010-03-22 AU AU2010201113A patent/AU2010201113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043461A1 (en) | 2004-05-27 |
| NO20052009D0 (no) | 2005-04-25 |
| NO20052009L (no) | 2005-06-27 |
| CN1720044A (zh) | 2006-01-11 |
| CA2504611A1 (en) | 2004-05-27 |
| AU2002348178A1 (en) | 2004-06-03 |
| BR0215935A (pt) | 2005-08-09 |
| EP1575582A4 (en) | 2009-03-11 |
| EP1575582A1 (en) | 2005-09-21 |
| MXPA05004711A (es) | 2005-08-03 |
| AU2010201113A1 (en) | 2010-04-15 |
| JP2006508119A (ja) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7804A (es) | Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico | |
| AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
| ECSP105178A (es) | Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos | |
| CL2008002139A1 (es) | Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer. | |
| CL2003002786A1 (es) | Composicion liofilizada que comprende i) una epotilona y ii) manitol o una ciclodextrina y composicion liofilizada que los comprende reconstituida con solvente, util como citotoxico en el tratamiento de tumores. | |
| UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
| MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
| CR11687A (es) | Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada | |
| MX2019010879A (es) | Tratamiento de cancer. | |
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CL2009001170A1 (es) | Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros. | |
| ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
| AR013269A1 (es) | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral | |
| CL2008001103A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros. | |
| WO2004087713A8 (en) | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases | |
| ES2572454T3 (es) | Tratamiento de enfermedades mediadas por los linfocitos T | |
| WO2008101214A3 (en) | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| AR051405A1 (es) | Compuestos de 2-carboxamido(3-amino)tiofeno | |
| ECSP034766A (es) | Una combinacion que comprende combretastatina y agentes anticancerigenos | |
| SV2009003403A (es) | Extrudidos con enmascaramiento del sabor mejorado | |
| WO2007087631A3 (en) | Cobalamin compositions for the treatment of cancer | |
| ECSP11011363A (es) | Derivados de quinoxalina y su uso para el tratamiento de tumores benignos y malignos | |
| EA200300427A1 (ru) | Противоопухолевая терапия, включающая производные дистамицина | |
| ITRM20030194A0 (it) | Uso di derivati del 7-nitro-2,1,3-benzossadiazolo per la terapia di forme tumorali. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |